ODTX Financials

Income Statement
MetricQ3 2026Q2 2026
Revenue
0
0
Cost of Revenue
0
0
Gross Profit
0
0
Operating Expenses
53.4M
-3.8%
55.5M
R&D
42.1M
+16.3%
36.2M
SG&A
11.2M
+6.9%
10.5M
Operating Income
-53361000
+3.8%
-55470000
EBITDA
-52352000
+3.8%
-54427000
Net Income
-53059000
-0.5%
-52788000
EPS (Basic)
$-1.10
+36.8%
$-1.74
EPS (Diluted)
$-1.10
+36.8%
$-1.74
Shares (Diluted)
48.0M
+58.6%
30.3M
Odyssey Therapeutics (ODTX) — Financials